← Eichor
Study identifier: NCT07195734 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Condition: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Locally Recurrent Head and Neck Squamous Cell Carcinoma  ·  Sponsor: National Cancer Institute (NCI)

PhasePhase 2
Planned participants180
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cisplatin for high risk patients, for the treatment of patients with PD-L1 positive head and neck squamous cell carcinoma that has come back and spread to nearby tissue or lymph nodes after a period of improvement (locally recurrent) or is persistent. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Salvage surgery is surgery that takes place to remove tumor tissue after a failure of other treatment. High risk patients also receive radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding chemotherapy or chemo-i…

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (100)

Banner University Medical Center - TucsonTucson, Arizona, United StatesRecruiting
University of Arizona Cancer Center-North CampusTucson, Arizona, United StatesRecruiting
USC / Norris Comprehensive Cancer CenterLos Angeles, California, United StatesRecruiting
Sutter Medical Center SacramentoSacramento, California, United StatesRecruiting
University of California Davis Comprehensive Cancer CenterSacramento, California, United StatesRecruiting
Emory Proton Therapy CenterAtlanta, Georgia, United StatesRecruiting
Emory University Hospital MidtownAtlanta, Georgia, United StatesRecruiting
Northwestern UniversityChicago, Illinois, United StatesRecruiting
Rush MD Anderson Cancer CenterChicago, Illinois, United StatesRecruiting
Northwestern Medicine Cancer Center KishwaukeeDeKalb, Illinois, United StatesRecruiting
Northwestern Medicine Cancer Center DelnorGeneva, Illinois, United StatesRecruiting
Northwestern Medicine Glenview Outpatient CenterGlenview, Illinois, United StatesRecruiting

+ 88 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07195734